BioXcel Therapeutics announces results from Phase 2 trial of BXCL701

BioXcel Therapeutics announced "promising" top-line data from its Phase 2 trial of BXCL701, the Company’s investigational, oral innate immune activator, in combination with KEYTRUDA in small cell neuroendocrine metastatic castration-resistant prostate cancer, SCNC, patients. Full data have been submitted to the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, ASCO GU. "We are pleased that BXCL701 in combination with pembrolizumab has demonstrated an encouraging response rate in this difficult-to-treat cancer with no currently approved FDA therapies," said Vincent J. O’Neill, M.D., Chief R&D Officer, OnkosXcel Therapeutics, a wholly owned subsidiary of BioXcel Therapeutics. "BXCL701’s promising profile as an oral innate immune activator with a large safety dataset and novel mechanism of action further supports OnkosXcel’s pipeline and use of BioXcel’s AI platform, and reinforces our confidence in BXCL701’s potential to enable checkpoint inhibitor therapy in traditionally cold cancers."